Across multiple Phase 3 trials, Eli Lilly and Company’s once-weekly insulin efsitora alfa matched daily basal insulin in A1C reduction and demonstrated a similar safety profile.
“The novel fixed-dose regimen … has the potential to facilitate and simplify insulin therapy, reducing the hesitation often associated with starting insulin to treat type 2 diabetes,” said Julio Rosenstock, MD, senior scientific advisor at Velocity and lead trial investigator for QWINT-1. “Across all QWINT trials, the results showed that once-weekly efsitora controlled glucose as effectively as the most popular once-daily basal insulins.”
Read the press release: https://investor.lilly.com/news-releases/news-release-details/first-its-kind-fixed-dose-study-once-weekly-insulin-efsitora
